EDEN.L

Eden Research Plc
Eden Research plc - Mevalone Organic Input Registration in Germany
11th December 2024, 07:00
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 5845P
Eden Research plc
11 December 2024
 

11 December 2024

 

Eden Research launches fundraise for up to £11 million to fund materials to build up stocks for its new seed treatment - Perivan

 

Eden Research

("Eden" or "the Company")

 

 

Mevalone® included in Organic Input List by FiBL Germany

 

Eden Research plc (AIM: EDEN), a leader in sustainable biopesticide and biocontrol products, is pleased to announce that its flagship fungicide, Mevalone®, has been registered as an input for organic farming in Germany.

 

The Input List for organic production in Germany is managed by the Research Institute of Organic Agriculture, FiBL, a European organisation with presence in several countries and with well-recognised and respected activities related to sustainability and organic farming. This inclusion has been granted by experts who evaluate farming inputs for their compliance with the requirements of organic production in Germany and multiple other countries.

 

The news follows the approval of Mevalone in Germany, announced in August 2024. Eden's German commercial partner, Sumi Agro Deutschland, which has a strong focus on supporting organic farmers, has reinforced the importance of having this registration by FiBL Germany to better address the needs of organic growers in Germany.

 

The registration for organic farming follows the German 2030 Organic Strategy that was released in November 2023. The German 2030 Organic Strategy, developed by the Federal Ministry of Food and Agriculture, outlines 30 measures the country will take with the aim of reaching 30% of organic farmland in Germany by 20301. This policy exceeds the 25% of organic farmland in the EU as set in the EU Green Deal and means that significant action is required by the entire agriculture sector to reach this goal. Therefore, the registration of Mevalone as an input for organic farming in Germany positions the product as a significant contributor to support German farmers to achieve their targets whilst also retaining productivity.

 

With FiBL Germany's addition of Mevalone to the Organic Input list, Eden expects its flagship fungicide to become an even more versatile product used by German organic growers to effectively control fungal diseases and to avoid production loss, whilst also remaining consistent with the requirements of organic agriculture.

 

Sean Smith, Chief Executive Officer of Eden Research plc, commented:

 

"Mevalone's inclusion in the Organic Input List by FiBL Germany provides us with another vital organic registration in an important market, following in the footsteps of Greece, Italy, and France.  Our products' organic compliance demonstrates their sustainable qualities based on Eden's terpene chemistry, as well as their strong efficacy, even when compared with conventional pesticides.

 

"Germany currently has approximately 10% of apple orchards and 15% of vineyard areas dedicated to organic farming, and indications show that these proportions of organic farmland are growing rapidly. Against this backdrop, we have strategically positioned Mevalone as one of the leading alternative fungicide products that fits both the conventional and organic farming needs."

 

1Federal Ministry of Food and Agriculture: 2030 Organic Strategy - National Strategy for 30 % Organic Food and Farming by 2030, https://www.bmel.de/EN/topics/farming/organic-farming/2030-organic-strategy.html)

 


- ENDS -

 

 

For further information contact:

 

Eden Research plc

www.edenresearch.com

Sean Smith
Alex Abrey

 

 

01285 359 555



Cavendish Capital Markets Limited (Nominated advisor and broker)


Giles Balleny / George Lawson (Corporate Finance)

Charlie Combe (Broking)
Michael Johnson (Sales)

 

 

020 7397 8900



Hawthorn Advisors (Financial PR)


Victoria Ainsworth

 

eden@hawthornadvisors.com

 

           


 

Notes to Editors:

 

Eden Research is the only UK-listed company focused on biopesticides for sustainable agriculture. It develops and supplies innovative biopesticide products and natural microencapsulation technologies to the global crop protection, animal health and consumer products industries.

 

Eden's products are formulated with terpene active ingredients, based on natural plant defence metabolites. To date, they have been primarily used on high-value fruits and vegetables, improving crop yields and marketability, with equal or better performance when compared with conventional pesticides. Eden has three products currently on the market:

 

Based on plant-derived active ingredients, Mevalone® is a foliar biofungicide which initially targets a key disease affecting grapes and other high-value fruit and vegetable crops.  It is a useful tool in crop defence programmes and is aligned with the requirements of integrated pest management programmes. It is approved for sale in a number of key countries whilst Eden and its partners pursue regulatory clearance in new territories thereby growing Eden's addressable market globally.

 

Cedroz is a bionematicide that targets free living nematodes which are parasitic worms that affect a wide range of high-value fruit and vegetable crops globally.  Cedroz is registered for sale on two continents and Eden's commercial collaborator, Eastman Chemical, is pursuing registration and commercialisation of this important new product in numerous countries globally.

 

Eden's seed treatment product, EcovelexÔ was developed to safely tackle crop destruction caused by birds - a major cause of losses in maize and other crops. Ecovelex works by creating an unpleasant taste or odour that repels birds, leaving the seeds safely intact and the birds unaffected and free to find alternative food sources. The product is based on Eden's plant-derived chemistry, registered in the EU, U.S. and elsewhere, and formulated using Eden's Sustaine® microencapsulation system.

 

Eden's Sustaine® encapsulation technology is used to harness the biocidal efficacy of naturally occurring chemicals produced by plants (terpenes) and can also be used with both natural and synthetic compounds to enhance their performance and ease-of-use. Sustaine microcapsules are naturally-derived, plastic-free, biodegradable micro-spheres derived from yeast. It is one of the only viable, proven and immediately registerable solutions to the microplastics problem in formulations requiring encapsulation.

 

Eden was admitted to trading on AIM on 11 May 2012 and trades under the symbol EDEN. It was awarded the London Stock Exchange Green Economy Mark in January 2021, which recognises London-listed companies that derive over 50% of their total annual revenue from products and services that contribute to the global green economy. Eden derives 100% of its total annual revenues from sustainable products and services.

 

For more information about Eden, please visit:  www.edenresearch.com.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
REAFFIFASELSEEE]]>
TwitterFacebookLinkedIn